Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir and lamivudine dual therapy in HIV-1 infection
NCT02263326Phase 3Completed
- Start
- Dec 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir and lamivudine in human immunodeficiency virus type 1 infection (HIV-1). Started Dec 2014; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02263326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263326.